Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sandeep Vaishnavi

Psychiatry Chapel Hill, NC Medical Doctor

NPI 1629116801 CMS profile 73911

1829 East Franklin Street, Building 400, Chapel Hill, NC 27514

Open in the dashboard

General payments

$26,954

88 records reported · program years 2019–2025

Research payments

$2,620

Paid to them · 12 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$388,377 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Sandeep Vaishnavi of Chapel Hill, NC is reported in the CMS Open Payments database as having received $26,954 across 88 general payments and $2,620 in research payments paid to them. Separately, studies naming them as principal investigator received $388,377 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $125 1
2024 General $1,960 1
2023 General $10,634 18
2022 General $12,873 14
2021 General $400 14
2020 General $148 9
2020 Research $1,409 6
2019 General $814 31
2019 Research $1,211 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sandeep Vaishnavi
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Sandeep Vaishnavi were reported at $125. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Sandeep Vaishnavi Psychiatry median Middle half National median
2019 $814 $184 $59–$605 $163
2020 $148 $119 $36–$372 $114
2021 $400 $143 $43–$576 $132
2022 $12,873 $153 $50–$590 $149
2023 $10,634 $170 $56–$651 $160
2024 $1,960 $179 $57–$673 $164
2025 $125 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $21,329 16 payments
  2. Brainsway USA Inc $3,623 5 payments
  3. LivaNova USA, Inc. $581 9 payments
  4. Neuronetics, Inc. $275 3 payments
  5. Otsuka America Pharmaceutical, Inc. $227 7 payments
  6. Janssen Pharmaceuticals, Inc $152 3 payments
  7. Sunovion Pharmaceuticals Inc. $132 7 payments
  8. Allergan Inc. $129 10 payments
  9. Lundbeck LLC $127 7 payments
  10. Alkermes, Inc. $69 3 payments
  11. Other $311 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $19,012 9 payments
  2. Food and Beverage $5,887 76 payments
  3. Travel and Lodging $2,055 3 payments
Products named General payments · program years 2019–2025
  1. BrainsWay Deep TMS $3,623 5 payments
  2. ABILIFY MYCITE $1,960 1 payment
  3. VNS Therapy Symmetry Model 8103 Generator $581 9 payments
  4. NEUROSTAR TMS THERAPY $275 3 payments
  5. REXULTI Psychiatry $191 5 payments
  6. INVEGA SUSTENNA $152 3 payments
  7. INVEGA TRINZA $137 2 payments
  8. LATUDA $132 7 payments
  9. VRAYLAR $129 10 payments
  10. REXULTI Psychiatry $87 4 payments
  11. Other $828 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $2,620 12 payments

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$18,053

Medicare's payments for the services billed

Medicare patients

41

Average age 75

Services billed

176

23 women, 18 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 66%
Arthritis 59%
Chronic kidney disease 51%
Ischemic heart disease 49%
Alzheimer's or dementia 49%
Heart failure 46%
Diabetes 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ABILIFY MYCITE
  • Otsuka Pharmaceutical Development & Commercialization, Inc. $1,960
$1,960 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record